Candel Therapeutics is developing viral immunotherapies that empower the immune system to fight cancer. The therapies aim to produce individualized responses specific to the patient and their cancer.

Candel Therapeutics

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.

Candel Therapeutics, Inc.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Oct 23, 2024 5:22 AM	7e73efc8
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Oct 23, 2024 5:22 AM	4dfb338b
crunchbase trigger	general	Nov 27, 2024 12:50 PM	cc0c0638
crunchbase profile	general
li profile	general
translate crunchbase fundingrounds	general
peers	general	Oct 23, 2024 5:22 AM	bf104d9a
news basic	general	Oct 23, 2024 5:22 AM	f8150a1c
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:CANDELTX

Candel Therapeutics

Last Close

4.13

22/11 21:00

Market Cap

178.24M

Beta: -

Volume Today

2.30M

Avg: -